Pharmacological inhibition of the ileal apical sodium-dependent bile acid transporter (ASBT/SLC10A2) followed by a decline in intestinal BA uptake was reported to ameliorate cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis [63]. This evidence concerns the gene SLC10A2 and sclerosing cholangitis.